Nutritional Status of Patients with Chronic Myeloid Leukemia Treated with Imatinib Mesylate.

Imatinib mesylate (IM) is the treatment of choice in patients with chronic myeloid leukemia (CML). Among its nonhematological adverse events, water retention is the most common, together with weight gain. However, no thorough description of the body composition in these patients has been informed.